Markets & Finance

Wachovia Keeps 'Market Perform' on Apria Healthcare


Wachovia keeps its market perform rating on Apria Healthcare (AHG).

Analyst William Bonello says Medicare reimbursement cuts included in the national prescription-drug bill is worse than he expected. He notes the respiratory drug reimbursement is set to be cut by 16% in 2004, and an additional 65% or more in 2005. He figures drug cuts could reduce earnings per share by about 18 cents in 2004 and 93 cents in 2005 -- all else held equal.

Furthermore, Bonello thinks bidding could limit growth rates in 2007 and beyond. While Apria has a competitive business model in a growing fragmented market, he thinks near-term appreciation may be limited due to potential changes in Medicare's reimbursement for respiratory therapy.


Race, Class, and the Future of Ferguson
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus